Literature DB >> 19597794

MetaMiner (CF): a disease-oriented bioinformatics analysis environment.

Jerry M Wright1, Yuri Nikolsky, Tatiana Serebryiskaya, Diana R Wetmore.   

Abstract

MetaMiner (CF) is a data analysis platform for a broad range of CF researchers including wet lab biologists, bioinformaticians, clinicians, and chemists. To understand disease mechanisms and gain insight into complex biological actions, analysis of even simple gene interactions often requires integration of a variety of separate data resources such as literature, 3D molecular models, metabolic pathways, ontologies, small molecules, and drugs. Large-scale data sets from high-throughput screening assays, microarrays, and other data intensive procedures present an even greater challenge in data handling and analysis which now requires interdisciplinary teams of scientists with strikingly diverse backgrounds including computer scientists, statisticians, biologists, and clinicians. To address the issues raised by the complexity of analysis and resource limitations of many research laboratories, MetaMiner (CF) was developed by GeneGo under direction and funding of Cystic Fibrosis Foundation Therapeutics. The platform was designed to provide the CF community with a single tool for analyzing experimental data in a disease-centered environment. To that end, the most important biological and chemical experimental data available today in cystic fibrosis research have been assembled and integrated with data analysis and visualization tools to highlight the key pathways leading to and perturbed by the disease. GeneGo developers assembled and edited CF-specific content and designed the disease-specific interface under the guidance and review of a team of leading cystic fibrosis experts. Updates and revisions will be processed quarterly under the direction of the CF Foundation Therapeutics.

Entities:  

Mesh:

Year:  2009        PMID: 19597794     DOI: 10.1007/978-1-60761-175-2_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  Hsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapy.

Authors:  Nadzeya V Marozkina; Sean Yemen; Molly Borowitz; Lei Liu; Melissa Plapp; Fei Sun; Rafique Islam; Petra Erdmann-Gilmore; R Reid Townsend; Cheryl F Lichti; Sneha Mantri; Phillip W Clapp; Scott H Randell; Benjamin Gaston; Khalequz Zaman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-08       Impact factor: 11.205

Review 2.  Emergent properties of proteostasis in managing cystic fibrosis.

Authors:  William E Balch; Daniela M Roth; Darren M Hutt
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

3.  Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.

Authors:  Mary J Emond; Tin Louie; Julia Emerson; Jessica X Chong; Rasika A Mathias; Michael R Knowles; Mark J Rieder; Holly K Tabor; Debbie A Nickerson; Kathleen C Barnes; Lung Go; Ronald L Gibson; Michael J Bamshad
Journal:  PLoS Genet       Date:  2015-06-05       Impact factor: 5.917

4.  Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and ΔF508-CFTR rescue.

Authors:  Rachel A Hodos; Matthew D Strub; Shyam Ramachandran; Li Li; Paul B McCray; Joel T Dudley
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

5.  Integrative chemogenomic analysis identifies small molecules that partially rescue ΔF508-CFTR for cystic fibrosis.

Authors:  Rachel A Hodos; Matthew D Strub; Shyam Ramachandran; Ella A Meleshkevitch; Dmitri Y Boudko; Robert J Bridges; Joel T Dudley; Paul B McCray
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.